Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory Melanoma or Other Solid Tumors With BRAF Fusions or CRAF/RAF1 Fusions or Amplification: Phase II FIRELIGHT-1 Substudy

Maria Vieito, Elena Garralda Cabanas, Inderjit Mehmi, Caroline Gaudy-Marqueste, Bert H. O'Neil, Theresa M. Medina, Amy L. Body, Ana Arance, Shivaani Kummar, Yana G. Najjar, Philippe L. Bedard, Andrew Rankin, Caroline Chu, Chris McKenna, Stephanie Hume, Lisa M. Kopp, Jeeyun Lee

Open source

DOI: 10.1200/po-25-01187
Published: 2026-10
Container: JCO Precision Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/po-25-01187,
  title = {Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory Melanoma or Other Solid Tumors With
                    <i>BRAF</i>
                    Fusions or
                    <i>CRAF/RAF1</i>
                    Fusions or Amplification: Phase II FIRELIGHT-1 Substudy},
  author = {Maria Vieito and Elena Garralda Cabanas and Inderjit Mehmi and Caroline Gaudy-Marqueste and Bert H. O'Neil and Theresa M. Medina and Amy L. Body and Ana Arance and Shivaani Kummar and Yana G. Najjar and Philippe L. Bedard and Andrew Rankin and Caroline Chu and Chris McKenna and Stephanie Hume and Lisa M. Kopp and Jeeyun Lee},
  year = {2026},
  journal = {JCO Precision Oncology},
  doi = {10.1200/po-25-01187},
  url = {https://doi.org/10.1200/po-25-01187}
}

RIS

TY  - JOUR
TI  - Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory Melanoma or Other Solid Tumors With
                    <i>BRAF</i>
                    Fusions or
                    <i>CRAF/RAF1</i>
                    Fusions or Amplification: Phase II FIRELIGHT-1 Substudy
AU  - Maria Vieito
AU  - Elena Garralda Cabanas
AU  - Inderjit Mehmi
AU  - Caroline Gaudy-Marqueste
AU  - Bert H. O'Neil
AU  - Theresa M. Medina
AU  - Amy L. Body
AU  - Ana Arance
AU  - Shivaani Kummar
AU  - Yana G. Najjar
AU  - Philippe L. Bedard
AU  - Andrew Rankin
AU  - Caroline Chu
AU  - Chris McKenna
AU  - Stephanie Hume
AU  - Lisa M. Kopp
AU  - Jeeyun Lee
PY  - 2026
JO  - JCO Precision Oncology
DO  - 10.1200/po-25-01187
UR  - https://doi.org/10.1200/po-25-01187
ER  -

APA

Vieito, M., Cabanas, E. G., Mehmi, I., Gaudy-Marqueste, C., O'Neil, B. H., Medina, T. M., Body, A. L., Arance, A., Kummar, S., Najjar, Y. G., Bedard, P. L., Rankin, A., Chu, C., McKenna, C., Hume, S., Kopp, L. M., & Lee, J. (2026). Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory Melanoma or Other Solid Tumors With BRAF Fusions or CRAF/RAF1 Fusions or Amplification: Phase II FIRELIGHT-1 Substudy. JCO Precision Oncology. https://doi.org/10.1200/po-25-01187

Source records

crossref · retrieved 2026-11-10T12:30:27.264Z

Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory Melanoma or Other Solid Tumors With <i>BRAF</i> Fusions or <i>CRAF/RAF1</i> Fusions or Amplification: Phase II FIRELIGHT-1 Substudy

Credibility signals

Cite this work

BibTeX

RIS

APA

Source records